Key result
The K146N myosin mutation prolonged cross-bridge binding to actin, increasing isometric force but decreasing power output, flight ability, and causing restricted cardiac physiology with diastolic dysfunction.
Why the study?
Does the K146N mutation in beta-cardiac myosin heavy chain alter cross-bridge kinetics and muscle function in a Drosophila model of hypertrophic cardiomyopathy?
Does the K146N mutation in beta-cardiac myosin heavy chain alter cross-bridge kinetics and muscle function in a Drosophila model of hypertrophic cardiomyopathy?
The K146N mutation causes hypertrophic cardiomyopathy phenotypes in Drosophila through prolonged cross-bridge binding, establishing a model that could be used for rapid screening of HCM alleles and treatments.
Answers are grounded in this paper and cite their sources.
Provides no immediate clinical implications for HCM; leaves open Drosophila models for rapid allele screening and therapy testing.
K146N is a dominant mutation in human β-cardiac myosin heavy chain, which causes hypertrophic cardiomyopathy. We examined how Drosophila muscle responds to this mutation and integratively analyzed the biochemical, physiological and mechanical foundations of the disease. ATPase assays, actin motility, and indirect flight muscle mechanics suggest at least two rate constants of the cross-bridge cycle are altered by the mutation: increased myosin attachment to actin and decreased detachment, yielding prolonged binding. This increases isometric force generation, but also resistive force and work absorption during cyclical contractions, resulting in decreased work, power output, flight ability and degeneration of flight muscle sarcomere morphology. Consistent with prolonged cross-bridge binding serving as the mechanistic basis of the disease and with human phenotypes, 146N /+ hearts are hypercontractile with increased tension generation periods, decreased diastolic/systolic diameters and myofibrillar disarray. This suggests that screening mutated Drosophila hearts could rapidly identify hypertrophic cardiomyopathy alleles and treatments.
No takes yet. Share an insight, caveat, or question.
Kronert et al. (2018) studied Hypertrophic cardiomyopathy. K146N myosin mutation vs. Wild-type transgenic myosin (PwMhc2) was evaluated. The K146N myosin mutation prolonged cross-bridge binding to actin, increasing isometric force but decreasing power output, flight ability, and causing restricted cardiac physiology with diastolic dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: